Medical Oncology

Uzm. Dr. Hakan Taban

Doctor and researcher Medical Park Ankara (Batıkent) Ankara

Lung NeoplasmsCarcinoma, Renal CellKidney NeoplasmsNeoplasmsCarcinoma, Transitional CellColonic NeoplasmsBreast Neoplasms

Open institution page

Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source

Lung Neoplasms 4 publications

Source: OpenAlex / PubMed MeSHView publications
Carcinoma, Renal Cell 4 publications
Kidney Neoplasms 4 publications
Neoplasms 3 publications
Carcinoma, Transitional Cell 2 publications
Colonic Neoplasms 2 publications
Breast Neoplasms 2 publications

Person ↔ Disease

Which topics does this doctor work on?

From source

Medical areas of interest stated by the doctor on the institution profile. Source: medicalpark.com.tr.

Meme kanseri
Akciğer kanseri
Gastrointestinal kanserler
Genitoüriner kanserler
Jinekolojik kanserler
Kemoterapi
İmmünoterapi
Hedefe yönelik tedaviler

Education and experience

From source

Experience

20122013 Kandıra Ecz. M. Kazım Dinç Hastanesi Acil Servis Hekimimedicalpark.com.tr
20182018 Gercüş Devlet Hastanesi İç Hastalıkları Uzmanımedicalpark.com.tr
20222024 Samsun Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Uzmanımedicalpark.com.tr

Education

20062012 Marmara Üniversitesi Tıp Fakültesi İngilizce Lisansmedicalpark.com.tr
20132017 Hacettepe Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalımedicalpark.com.tr
20182022 Hacettepe Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı Yan Dal Uzmanlıkmedicalpark.com.tr

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

SpecialtyMedical Oncologymedicalpark.com.trFrom source
Department name at the sourceMedikal Onkoloji (Tıbbi Onkoloji)medicalpark.com.trFrom source
InstitutionMedical Park Ankara (Batıkent)medicalpark.com.trFrom source
Area of workLung NeoplasmsExtracted from 4 publications · Model version —From source
Publications54 publicationsOpenAlex, ORCID, Europe PMCFrom source
ORCID0000-0002-2004-7741ORCIDFrom source
Last synchronised4 November 2026 20:50https://www.medicalpark.com.tr/hekimler/hakan-tabanmedicalpark.com.tr

Scientific work

Publications on Lung Neoplasms

54 publications

Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma

Immunotherapy, 2026

DOI 10.1080/1750743x.2026.2722548 PMID 42683510 Open-access full textSource: OpenAlex
Association of Cabazitaxel Treatment Beyond 10 Cycles with Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer: A Retrospective 8-Month Landmark Analysis

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15186966 PMID 42795739 Open-access full textSource: ORCID
Synchronous Adrenocortical Carcinoma, Renal Cell Carcinoma, and Mediastinal Mature Teratoma with Heterozygous Variants in SMARCA4, APC, and MYBP3: A Case Report

Journal of Oncological Sciences, 2026

DOI 10.37047/jos.galenos.2026.2025-10-7 Open-access full textSource: ORCID
Clinical Characteristics and Survival Outcomes of a Clinically Defined Treatment-Emergent Neuroendocrine/Aggressive-Variant Prostate Cancer Phenotype: A Retrospective Study

Medicina, 2026

DOI 10.3390/medicina62091702 PMID 42796309 Open-access full textSource: ORCID
Prognostic Significance of SULF2 Expression in Surgically Resected Non-Small Cell Lung Cancer

Medical sciences (Basel, Switzerland), 2026

DOI 10.3390/medsci14020215 PMID 42201007 Open-access full textSource: Europe PMC
Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program

Future Oncology, 2025

DOI 10.1080/14796694.2025.2570637 PMID 41103123 Open-access full textSource: OpenAlex
Prognostic Nutritional Index and a Blood-Based Prognostic Tool in Prostate Cancer Treated with Abiraterone, Enzalutamide or Cabazitaxel

Medicina, 2025

DOI 10.3390/medicina61061105 PMID 40572794 4 citations (Europe PMC) Open-access full textSource: ORCID
Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning Approach

Cancers, 2025

DOI 10.3390/cancers17020233 PMID 39858018 1 citation (Europe PMC) Open-access full textSource: Europe PMC
Evaluation of treatment regimens and prognostic factors in primary central nervous system lymphomas

Journal of Current Hematology & Oncology Research, 2025

DOI 10.51271/jchor-0062 1 citation (OpenAlex) Open-access full textSource: OpenAlex
The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancer

Acta Medica, 2025

DOI 10.32552/2025.actamedica.1159 Open-access full textSource: OpenAlex

View all 54 publications

Other doctors working on these diseases

Memberships and more

2018 Türk Tıbbi Onkoloji Derneği
2019 Onkoloji ve İmmünoterapi Derneği
2019 European Society for Medical Oncology
2020 European School of Oncology

Courses and certificates (5)

2020 ESMO Virtual Congress
2021 İstinye Üniversitesi Sürekli Eğitim Merkezi İyi Klinik Uygulamalar Sertifikası
2022 20th Western Europe Masterclass in Medical Oncology İspanya
2022 Tıbbi Onkoloji Yeterlilik Belgesi Türk Tıbbi Onkoloji Derneği
2023 ESMO Examination Certificate Avrupa Medikal Onkoloji Derneği Yeterlilik Belgesi

Source: medicalpark.com.tr

Ask Doctoria AI

Coming soon

In preparation for doctors, institutions and research teams. Examples of questions you will be able to ask:

Find the doctors with the most publications in Medical Oncology Find the researchers scientifically closest to this profile Find researchers for a multicentre study

Let’s improve this profile together

Every change is stored with its source, contributor and date.

Suggest a correction Add a publication Correct the institution Add a specialty Merge a duplicate record Claim profile

Last change: 47 yayın ORCID kimliğiyle eklendi Source: https://orcid.org/0000-0002-2004-7741
Contributor: Doctoria bot
Date: 6 November 2026 17:46